Can Up Move Continue for Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX)

Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) gained 64.8% on huge volume in Friday’s trading session to end the week at $0.53 a share. However, the biopharmaceutical company continues to trade in a strong downtrend after coming under pressure earlier this year.

Repros Therapeutics Inc. (NASDAQ:RPRX) is down by more than 50% for the year as investor confidence on the stock continues to drop. Failure of the company to turn in a profit from in recent years has been the focal point of concern for investors.

Repros Therapeutics Inc. (NASDAQ:RPRX)

Financial Results Concern

For the three months ended June 30, 2017, Repros Therapeutics Inc. (NASDAQ:RPRX) posted a net loss of (-$2.2) million or (-$0.08) a share, compared to a net loss of (-$4.3) million reported last year. The company attributes the decrease to lower clinical development expenses relating to Proellex and enclomiphene.

Net Loss for the first six months of the year totaled $8.1 million compared to $9.1 million for the corresponding period last year. Total revenue and income decreased to $7,000 for the three months ended June 30, 2017, compared to $15,000 reported last year. The decrease was primarily due to lower cash balance as compared to the corresponding period last year.

General and Administrative expenditure dropped 14% in the second quarter to $906,000 due to a decrease in non-cash stock-based compensation. However, the expenditure was up by 121% for the first six months of the year to $4.7 million, mainly because of a $2.8 million charge relating to the departure of a former executive.

Repros Therapeutics Inc. (NASDAQ:RPRX) had cash and cash equivalents of $3.8 million as of June 30, 2017, compared to $8.7 million as of December 31, 2017. The decline was primarily due to increased expenditure on clinical development programs as well as administrative costs. No funds were used for investing purposes in the first half of the year.

Investors are closely awaiting the outcome of the third quarter financial results. Depending on its outcome the stock could trade in either way as it will highlight the company’ long-term prospects heading into the year-end.

Class Action Lawsuit

Separately, Repros Therapeutics Inc. (NASDAQ:RPRX) is facing a wave of class action lawsuits over claims its officers and directors engaged in securities fraud and other unlawful business practices. The claims stem from a decision by the U.S. Food and Drug Administration to place the company’s Proellex program on clinical hold pending the review of all existing liver function safety data.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

FDA Notice Slams Repros Therapeutics Inc (NASDAQ:RPRX) Shares

Repros Therapeutics Inc (NASDAQ:RPRX)

Repros Therapeutics Inc (NASDAQ:RPRX) announced this morning that it had received some bad news from the U.S. Food and Drug Administration (FDA). The market reacted by sending RPRX shares over 30% lower to trade around the $0.40 mark. Volumes have been exceptionally heavy – almost forty times their average.

Repros Therapeutics Inc (NASDAQ:RPRX)
$RPRX Shares Crater

Woodlands, TX-based Repros Therapeutics Inc (NASDAQ:RPRX) develops and commercializes drugs designed to address reproductive disorders in both men and women. Today the company announced that they had received a notice from the FDA on Repros’ clinical development program for Proellex®. FDA informed Repros Therapeutics that the program will remain on partial “clinical hold”. This development stems from the FDA’s review of the safety data on the liver function. Accordingly, the FDA has suggested that a large safety database will need to be created to support any future development efforts.

Larry Dillaha, MD, Chief Executive Officer of Repros Therapeutics Inc (NASDAQ:RPRX), said, “We are appreciative of the preliminary feedback received from the FDA and expect further clarification from the FDA in the coming weeks on our Proellex® development program. Our discussions with the FDA, and their guidance that a large safety data base will be required to continue the development of Proellex®, indicate that a much larger clinical trial, with associated time and cost requirements, would be necessary.”

At the end of 2013, RPRX shareholders were looking at a share price approaching $30. However, pre-revenue Repros Therapeutics Inc (NASDAQ:RPRX) has yet to post a profit and over the years investors lost interest. Since May, RPRX shares have been trading below $1.

In 2012 shareholders had a per share loss of (-$1.23). Subsequent years experienced similar loss levels and in 2016 the loss shrank to (-$0.70). At the same time, shareholders have been getting diluted as the number of shares outstanding has increased from 15.35 million in 2012 to 24.66 million in 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author:  Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Repros Therapeutics Inc (NASDAQ:RPRX) Announces Pricing of $3.0 Million Public Offering

Repros Therapeutics Inc (NASDAQ:RPRX)

Repros Therapeutics Inc (NASDAQ:RPRX) has entered into an underwriting agreement that will see the company sell a total of 2,744,125 shares of the Company’s common stock in a public offering. The agreement will also involve issuing pre-funded Series C warrants to buy 2,245,875 shares of Common Stock that will be offered in lieu of Common Stock to those purchasers whose purchase of Common Stock in the offering otherwise would result in the purchaser beneficially owning over 4.99% of the Company’s outstanding common stock after the completion of the offering.

Additionally, Repros Therapeutics Inc (NASDAQ:RPRX) has issued Series A warrants to buy 3,742,500 shares of Common Stock plus Series B warrants issued to buy a total of 2,495,000 shares of Common Stock. There is no defined public trading market for the warrants, and the company is not expecting any such market to develop.

All shares of common stock will be paired with one Series A Warrant to buy 0.75 share of Common Stock together with one Series B Warrant to buy 0.5 share of Common Stock at a combined price of $0.60. All pre-funded warrants will be paired and sold with one Series A Warrant to buy 0.75 shares of Common Stock plus one Series B Warrant to buy 0.5 shares of common stock at a price of $0.60. The shares of common stock will be issued separately but purchased together.

Every Series A Warrant will be priced at $0.84 per share of Common Stock and will be exercisable from the issuance date up to five years from the first day they are exercisable. Every Series B warrant will be prices at $0.92 per share of Common Stock and will also be exercisable from the issuance date up to five years from the first day they are exercised. Every Pre-Funded Warrant will be priced at $0.001 per share of Common Stock and will be exercisable after issuance and will expire after two years from the first day they are exercised.

Repros Therapeutics Inc (NASDAQ:RPRX) expects to raise a total of $3.0 million in gross proceeds from the offering. After deducting all commission and underwriting discount plus other expenses related to the offering, the company expects net proceeds to amount to around $2.5 million. The proceeds from the offering will be used to fund the company’s general, administrative and corporate purposes. The company will close the offering on or around May 23, 2017, subject to the satisfaction of customary closing conditions.

Repros Therapeutics Inc (NASDAQ:RPRX) gained 17.95% and closed its day at $0.460.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Repros Therapeutics Inc (NASDAQ:RPRX) Holds Meeting With FDA To Discuss Oral Proellex® In The Treatment Of Uterine Fibroids

Repros Therapeutics Inc (NASDAQ:RPRX)

Repros Therapeutics Inc (NASDAQ:RPRX) has announced a meeting with the U.S Food and Drug Administration to discuss the progress in the development of Proellex® (telapristone acetate) – a treatment for uterine fibroids. Just before the meeting, the company was issued a notice that the meeting would be a Guidance of type C meeting and not an End of phase 2 of type B meeting as earlier expected.

During the meeting the FDA said that Proellex® will remain on a partial clinical hold as consultations between the agency and liver experts continue. Additionally, the agency agreed to take in the additional information provided by the company. Repros will also be submitting a proposed clinical protocol and additional information in a month’s time. The company will be making all information public after receiving more guidance from the FDA.

Repros President and Chief Executive Officer Larry Dillaha, M.D said they are pleased with the guidance, adding that although they are still on a partial clinical hold, the company will continue working on the plan by submitting phase 2 protocols to the FDA for review.

Repros Therapeutics also announced a new patent – U.S. Patent number 9,616,074 or the ‘074 patent which confirms the company’s intellectual property in relation to telapristone acetate which markets under the brand name Proellex®. The patent is expected to expire in 2027. The patent details the use of Progesterone Receptor Modulators (SPRM), especially the use of Telapristone Acetate (Proellex®) also referred to as the Ulipristal Acetate which has an Off Drug Interval (ODI) and is used in the treatment of hyperproliferative uterine conditions using estrogen. These include endometriosis and uterine fibroids. According to the terms of the patent, Off Drug Interval refers to a daily administration of the SPRM over a specified period of time and then followed by enough ODI to allow the patient to menstruate. This is followed by another period of SPRM administration.

Ticker RPRX
Market Cap $32.04M
P/E
EPS (ttm) -$0.7
Shares Outstanding 26.70M
Shares Float 26.45M
Insider Ownership 1.40%
Float Short 2.28%
Short Ratio 4.81
Performance (Quarter) -14.29%
Performance (Year) -47.14%
Performance (YTD) -9.09%
Beta -0.77
Average Volume 125.68K
Price $1.2
Volume 680,600
Target Price $5.25

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

Repros Therapeutics Inc (NASDAQ:RPRX) Appoints New CEO

Repros Therapeutics Inc (NASDAQ:RPRX)

Repros Therapeutics Inc (NASDAQ:RPRX) reported that Joseph S. Podolski is resigning from his role of President, CEO, and Board-member to pursue other interests. As a result, Larry Dillaha, M.D., who is the CEO of CavtheRx, was engaged as interim CEO and President of the firm, effective immediately.

The update

Patrick Fourteau, the Chairman of the Board for Repros Therapeutics Inc (NASDAQ:RPRX), said that as the company continues to boost its pipeline, the board will be performing a search for a CEO with extensive and appropriate experience to direct the firm’s next phase of growth. The company is grateful for Podolski’s numerous years of dedication to company and wishes him success in his future plans.

Prior to becoming Chief Executive Officer of CavtheRx, Dr. Dillaha was Chief Medical Officer and Chief Operating Officer of New Haven Pharmaceuticals, which is a specialty pharmaceutical firm. He also worked as Chief Medical Officer of Sciele Pharma, Insys Therapeutics, and as Medical Director of Sanofi-Sythelabo. He earned his M.D. from the University of Tennessee.

Repros Therapeutics Inc (NASDAQ:RPRX) focuses on the advancement of small molecule medications for major unmet medicinal needs that treat female and male reproductive disorders. Earlier in January, the company reported that the FDA has permitted an “end of Phase II” meeting to discuss the Phase III requirements intended to showcase both safety and efficacy for the advancement of Proellex® for the cure of uterine fibroids. The meeting is planned to occur before the close of April 2017.

In the Phase II trial Proellex® induced amenorrhea in greater than 90% 6 and 12 mg doses as against placebo of subjects subsequent to two 18-week cure cycles alienated by an off medicine interval to permit for menstruation. The patient group treated with Proellex® experienced statistical improvement when compared with the control group.

Repros Therapeutics Inc (NASDAQ:RPRX) reported that the study was performed in the United States with the average age of trial participants being less than 40 years of age, with a BMI less than 30, and more than 90% of the patients were African American. The data states that African American women are three times more likely to get symptomatic fibroids and, in fact, earlier in life than Caucasians. Reports suggest that the medicine was generally well tolerated.

In the last trading session, the stock price of Repros gained more than to close the trading session at $1.25. After the recent gains, the market cap of firm stands at $31.86 million.

3/15/2017
Ticker Symbol RPRX
Last Price a/o 3:21 PM EST  $1.25
Average Volume  132.58K
Market Cap (mlns)  $31.86M
Shares Outstanding (mlns) 25.49M
Share Float (mlns) 25.20M
Inside Ownership 1.50%
Short Float 2.59%
Short Interest Ratio 4.93
Quarterly Return -17.22%
YTD Return -5.30%
Year Return 20.19%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.